With deeper mechanistic insights and the development of selective inhibitors, ALKBH5 holds great promise as a novel immunotherapeutic target and predictive biomarker, offering new avenues and strategies to enhance the efficacy and precision of cancer immunotherapy. This evidence concerns the gene ALKBH5 and cancer.